Dronabinol Shows Promise for PTSD-Related Nightmares in Randomized Controlled Trial
Key Insights
A randomized controlled trial evaluated dronabinol, a synthetic cannabinoid, for treating nightmares in patients with post-traumatic stress disorder (search) (PTSD).
The study addresses a significant unmet need, as sleep disturbances and nightmares are core features of PTSD that often resist standard pharmacotherapy.
Dronabinol's mechanism leverages the endocannabinoid system (search), which is implicated in fear regulation and sleep stability, offering a novel therapeutic approach.
A newly published randomized controlled trial has investigated the efficacy of dronabinol, a synthetic form of delta-9-tetrahydrocannabinol (THC), for the treatment of nightmares in patients with post-traumatic stress disorder (search) (PTSD). The study, published in Nature Medicine, represents a significant step toward addressing one of the most distressing and treatment-resistant symptoms of PTSD.
The Burden of PTSD-Related Sleep Disturbance
Post-traumatic stress disorder (search) affects a substantial portion of the global population, with the World Mental Health Surveys estimating significant prevalence across countries. Sleep disturbances, particularly trauma-related nightmares, are not merely secondary symptoms but are increasingly recognized as a core feature of the disorder. As Spoormaker and Montgomery noted in their review, disturbed sleep in PTSD may represent a primary pathology rather than a downstream consequence.
Current pharmacotherapeutic options for PTSD-related nightmares remain limited. Prazosin, once widely used, has shown mixed results in large-scale trials, including a notable trial in military veterans that failed to demonstrate significant benefit over placebo. Antidepressants, while commonly prescribed for PTSD, have shown variable effects on sleep quality disturbances, and some agents—including fluoxetine, mirtazapine, and bupropion—have been associated with inducing or worsening nightmares.
The Endocannabinoid Rationale
The rationale for using dronabinol in PTSD is grounded in the role of the endocannabinoid system (search) in regulating fear, anxiety, and sleep. Research has demonstrated that endocannabinoid signaling regulates sleep stability and modulates cortical activity during non-REM sleep. Furthermore, the endocannabinoid system has been identified as a therapeutic target in PTSD, with molecular targets for modulating fear and anxiety.
Hill and colleagues have argued for integrating endocannabinoid signaling and cannabinoids into the biology and treatment of PTSD, while Steardo et al. systematically reviewed the endocannabinoid system (search) as a therapeutic target for the disorder. Observational studies have also noted that many military veterans with PTSD use cannabinoids, and posttraumatic stress symptom severity has been found to predict marijuana use coping motives among trauma-exposed individuals.
Prior Evidence and Trial Context
Earlier preliminary work provided a foundation for this trial. Fraser reported on the use of a synthetic cannabinoid in managing treatment-resistant nightmares in PTSD. Jetly and colleagues conducted a randomized, double-blind, placebo-controlled crossover study of nabilone, another synthetic cannabinoid, demonstrating efficacy for PTSD-associated nightmares. Roitman et al. published an open-label pilot study of add-on oral delta-9-THC in chronic PTSD, while Cameron and colleagues retrospectively evaluated synthetic cannabinoid use in a correctional population for PTSD-related insomnia and nightmares.
Trial Design and Endpoints
The multicenter randomized controlled trial employed a rigorous design to assess dronabinol's impact on PTSD-related nightmares. The study utilized the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), which has demonstrated strong psychometric properties in military veterans, alongside the PTSD Checklist for DSM-5 (PCL-5) for self-reported symptom assessment. Sleep-specific measures included the Pittsburgh Sleep Quality Index Addendum for PTSD and the Consensus Sleep Diary for prospective sleep self-monitoring.
Secondary assessments captured depressive symptoms using the Montgomery-Åsberg Depression Rating Scale, quality of life via the EuroQol instrument, and social functioning measures. The trial also monitored cannabis withdrawal symptoms using validated instruments, acknowledging the importance of assessing tolerability and dependence potential.
Clinical Significance
The findings carry important implications for clinical practice. Current evidence-based treatments for PTSD leave many patients with unresolved nightmares, and the existing pharmacopeia includes agents that may paradoxically worsen dream-related symptoms. Beta-blockers, SSRIs, levodopa, and promethazine have all been documented to affect dreaming, with some inducing vivid dreams or nightmares as adverse effects.
By targeting the endocannabinoid system (search), dronabinol offers a mechanistically distinct approach that may benefit patients who have not responded to or cannot tolerate existing therapies. The study protocol, previously published in BMC Psychiatry, outlined a design intended to provide robust evidence for this indication.
Looking Forward
As the therapeutic use of cannabis and cannabinoids continues to be systematically reviewed, this trial contributes important data to an evolving field. The results may inform treatment guidelines and expand the evidence base for cannabinoid-based pharmacotherapy in psychiatric indications, where systematic reviews have called for more rigorous randomized controlled trials.